Annamycin turns cold pancreatic tumors 'hot' in new preclinical data
Preclinical data suggests that Moleculin Biotech's lead candidate Annamycin stimulates antitumor activity via CD8+ T cells in pancreatic cancer, validating a potential immune-based mechanism of action alongside standard cytotoxicity.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed